SPP1 and breast carcinoma: Our work, combined with published studies on MDA-MB-231 cells, argue that targeting OPN in claudin-low breast cancers may prove to be an effective therapeutic approach however a more complete understanding of the OPN-receptor interactions as well as development of potent/specific OPN inhibitors are required to translate this strategy from the pre-clinical to clinical setting.